JAK2 and temporal arteritis: The benefit of JAK inhibition in patients with GCA is currently unknown but a phase 2 trial evaluating baricitinib (oral selective JAK1, JAK2 inhibitor) in patients with relapsing GCA is currently ongoing (ClinicalTrials.gov Identifier NCT03026504).